Barely Significant
← all excerpts

Impact of Sequential Ramucirumab Plus Docetaxel After PD-1 Inhibitors on Anti-PD-1 Antibody-Bound T-Cell Dynamics and Clinical Outcomes.

Cancer Sci · 2026 · PMC13045383 · PMID 41618119

Europe PMCDOI
1
hedged sentence
0.0500
closest p · 1.0× alpha
0.0500
boldest claim

The sentences

showed a trendp = 0.05actually significant
Within IgG4 + CD8 + T‐cell subsets, Temra showed a trend toward longer PFS in the high versus low groups (6.2 vs. 4.5 months, p = 0.05) and was significantly associated with longer OS (NR vs. 8.2 months, p = 0.006; Figure 3 ).

also in 42,889 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.